ka$h's Penny Breakroom

[fla-trader]

SHMN: announced the addition of 6 new generic pharmaceutical products targeting asthma and respiratory disease. India's respiratory drug market size is approximately $600 million annually. Acute respiratory diseases in India have grown by 33 percent from 2005-2010 which is a significantly higher growth rate compared to other communicable diseases.

Respiratory diseases are one of the most common forms of ill-health plaguing the Indian population today. They are also a leading cause of hospitalization and death. Allergic respiratory disorders, in particular asthma, have recorded abnormally high levels in India. Even though genetic predisposition is one of the main factors of respiratory disease there is an increased prevalence due to urbanization, air pollution and environmental tobacco smoke.